The DOI matches its Crossref record.
Daclizumab to Prevent Rejection after Cardiac Transplantation
Open accessAbstract
BACKGROUND: Daclizumab, a humanized monoclonal antibody against the interleukin-2 receptor, reduced the risk of rejection without increasing the risk of infection among renal-transplant recipients and, in a single-center trial, among cardiac-transplant recipients. We conducted a multicenter, placebo-controlled, double-blind study to confirm these results in cardiac-transplant patients. METHODS: We randomly assigned 434 recipients of a first cardiac transplant treated with standard immunosuppression (cyclosporine, mycophenolate mofetil, and corticosteroids) to receive five doses of daclizumab or placebo. The primary end point was a composite of moderate or severe cellular rejection, hemodynamically significant graft dysfunction, a second transplantation, or death or loss to follow-up within six months. RESULTS: By six months, 104 of 218 patients in the placebo group had reached the primary end point, as compared with 77 of the 216 patients in the daclizumab group (47.7 percent vs. 35.6 percent, P=0.007), a 12.1 percent absolute risk reduction and a 25 percent relative reduction. The rate of rejection was lower in the daclizumab group than in the placebo group (41.3 percent vs. 25.5 percent). Among patients reaching the primary end point, the median time to the end point was almost three times as long in the daclizumab group as in the placebo group during the first 6 months (61 vs. 21 days) and at 1 year (96 vs. 26 days). More patients in the daclizumab group than in the placebo group died of infection (6 vs. 0) when they received concomitant cytolytic therapy. CONCLUSIONS: Daclizumab was efficacious as prophylaxis against acute cellular rejection after cardiac transplantation. Because of the excess risk of death, concurrent or anticipated use of cytolytic therapy with daclizumab should be avoided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Costanzo, M. R., Costanzo, M. R., Dipchand, A., Starling, R., Anderson, A., Chan, M., Desai, S., Fedson, S., Fisher, P., Gonzales-Stawinski, G., et al. (2010) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2010.05.034 · Cited by 1,653
Self-citationGene-Expression Profiling for Rejection Surveillance after Cardiac Transplantation
Pham, M. X., Teuteberg, J. J., Kfoury, A. G., Starling, R. C., Deng, M. C., Cappola, T. P., Kao, A., Anderson, A. S., Cotts, W. G., Ewald, G. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912965 · Cited by 520
Self-citationAkl, E. A., Briel, M., You, J. J., Sun, X., Johnston, B. C., Busse, J. W., Mulla, S., Lamontagne, F., Bassler, D., Vera, C., et al. (2012) · BMJ · doi:10.1136/bmj.e2809 · Cited by 350
Adverse side‐effects to biological agents
Pichler, W. J. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01058.x · Cited by 283
Wakankar, A. A., & Borchardt, R. T. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20740 · Cited by 254
Metadata
- Authors
- Hershberger, R. E., Starling, R. C., Eisen, H. J., Bergh, C.-H., Kormos, R. L., Love, R. B., Van Bakel, A., Gordon, R. D., Popat, R., Cockey, L., & Mamelok, R. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-30
- Volume
- 352
- Issue
- 26
- Pages
- 2705-2713
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133842584
- Cited by
- 205
- References
- 0
- FWCI
- 21.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Daclizumab to Prevent Rejection after Cardiac Transplantation. https://app.cochat.ai/papers/10.1056/nejmoa032953
- The paper
- Hershberger, R. E., Starling, R. C., Eisen, H. J., Bergh, C.-H., Kormos, R. L., Love, R. B., Van Bakel, A., Gordon, R. D., Popat, R., Cockey, L., & Mamelok, R. D. (2005). Daclizumab to Prevent Rejection after Cardiac Transplantation. New England Journal of Medicine. https://doi.org/10.1056/nejmoa032953
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.